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Abstract
Background: Both syringe exchange programs (SEPs) and pharmacy sales of syringes are available
in Estonia, though the current high incidence and high prevalence of HIV among injection drug users
(IDUs) in Tallinn, Estonia requires large-scale implementation of additional harm reduction
programs as a matter of great urgency. The aims of this report were to compare risk behavior and
HIV infection and to assess the prevention needs among IDUs who primarily use pharmacies as
their source of sterile syringes with IDUs who primarily use SEPs in Tallinn.
Methods: A cross-sectional study using respondent-driven sampling was used to recruit 350 IDUs
for an interviewer-administered survey and HIV testing. IDUs were categorized into two groups
based on their self-reported main source for syringes within the last six months. Odds ratios with
95% CI were used to compare characteristics and risk factors between the groups.
Results: The main sources of sterile needles for injection drug users were SEP/SEP outreach (59%)
and pharmacies (41%). There were no differences in age, age at injection drug use initiation, the
main drug used or experiencing overdoses. Those IDUs using pharmacies as a main source of
sterile needles had lower odds for being infected with either HIV (AOR 0.54 95% CI 0.33–0.87) or
HCV (AOR 0.10 95% CI 0.02–0.50), had close to twice the odds of reporting more than one sexual
partner within the previous 12 months (AOR 1.88 95% CI 1.17–3.04) and engaging in casual sexual
relationships (AOR 2.09 95% CI 1.24–3.53) in the last six months.
Conclusion: The data suggest that the pharmacy users were at a less "advanced" stage of their
injection career and had lower HIV prevalence than SEP users. This suggests that pharmacies could
be utilized as a site for providing additional HIV prevention messages, services for IDUs and in
linking IDUs with existing harm reduction services.
Published: 20 February 2009
Harm Reduction Journal 2009, 6:3 doi:10.1186/1477-7517-6-3
Received: 16 September 2008
Accepted: 20 February 2009
This article is available from: http://www.harmreductionjournal.com/content/6/1/3
© 2009 Vorobjov et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Harm Reduction Journal 2009, 6:3 http://www.harmreductionjournal.com/content/6/1/3
Page 2 of 8
(page number not for citation purposes)
Background
More than twenty-five years into the pandemic, HIV infec-
tion continues to spread worldwide. The most recent epi-
demic has emerged in Eastern Europe. In 2001, the
Russian Federation reported 60.24 new HIV cases per
100,000 population; Estonia reported 49.17 and Latvia
33.29 [1]. Although the number of new cases in 2006 had
declined to 27 per 100,000 in Russia and 13 in Latvia, the
incidence rate in Estonia is still notably high at 50 per
100,000 [1]. Injection drug use is the main cause of this
prolonged HIV outbreak and according to the Joint
United Nations Programme on HIV/AIDS the sharing of
needles and syringes (referred to collectively, for the pur-
poses of this study, as "syringes") are the key factors in
transmitting around 80% of HIV infections in this region
[2]. Studies in other locations have shown that HIV infec-
tion among injection drug users (IDUs) may lead to self-
sustained heterosexual transmission of the virus [3].
Although syringe exchange programs (SEP) have been
shown to be an effective response to injection-related HIV
risks, there are too few SEPs, with limited hours of opera-
tion, to meet the needs of the growing IDU population [3-
5]. Previous studies have shown that pharmacies can be
an alternative source for sterile syringes and a venue for
providing other services to IDUs [6-10]. Pharmacies are
already involved in providing treatment for addiction, dis-
pensing methadone, supervising methadone consump-
tion and providing information on drug misuse and HIV
prevention [6,7,9]. Pharmacies have also participated in
syringe exchange and distributing or selling low price kits
containing injecting equipment [6,8,10]. However, data
on the use of pharmacies as a source of sterile syringes in
Eastern European countries and Russia is lacking.
Syringe exchange began in Estonia in 1997 [11]. At the
end of 2006 there were 26 SEPs, located in high drug use
areas (in Tallinn and in the North-Eastern part of Estonia)
[12]. The SEPs provide additional services besides syringe
exchange (health education, social welfare advice, referral
for blood-borne virus testing, medical and drug treat-
ment). Over-the-counter sterile syringes are available in
Estonian pharmacies without prescription.
In a location with high HIV incidence and prevalence
among IDUs, limited resources, and evidence of high risk
injection practices among IDUs, we need to understand
the factors associated with getting injection equipment
from different sources. Previous studies of HIV among
IDUs in Estonia have examined prevalence and risk
behavior among the samples either as a whole or by
demographic subgroups [13-16]. Our aims were to exam-
ine the levels of risk behavior and the levels of HIV infec-
tion and to assess the prevention needs among IDUs who
primarily use pharmacies as their source of sterile syringes
and to compare them with IDUs who primarily use SEPs
in Tallinn.
Methods
Respondent-driven sampling (RDS) [17,18] was used to
recruit 350 current IDUs for a cross-sectional risk behavior
survey and biological sample collection for HIV testing.
The study was conducted in spring 2007, in Tallinn. Inclu-
sion criteria were being 18 years or older, Russian or Esto-
nian language speakers, use of injection drugs in the
previous two months and ability to provide informed
consent. The inclusion criterion of drug use within two
months was used with the aim of recruiting current IDUs.
Recruitment began with the non-random selection of five
"seeds" representing diverse IDU types (by gender, ethnic-
ity, main type of drug used, engaging in sex for money and
HIV status). Eligible participants were provided with cou-
pons for recruiting up to three of their peers. Coupons
were uniquely coded to link participants to their survey
responses and biological specimens and for monitoring
who recruited whom. Participants who completed the
study received a primary incentive (a food coupon worth
6.4 EUR) for participation in the study and a secondary
incentive (food coupons worth 3.2 EUR for each eligible
person they recruited to the study). The RDS technique
uses participants' social networks to access individuals
who may not appear in public venues and are not in con-
tact with service providers. Data collected using RDS can
be generalized to the sampled population when informa-
tion about recruitment patterns (who recruited whom),
network connections and social network sizes are gath-
ered and incorporated into the analysis of estimates and
confidence intervals [19,20].
We used an interviewer-administered questionnaire, in a
face-to-face interview setting, based on the WHO Drug
Injecting Study Phase II survey (version 2b (rev.2)) [21].
In order to assess local conditions and to subsequently
adjust the instrument to best fit Tallinn's IDUs, we gath-
ered information during a rapid assessment in October,
2006. Questions were selected that would elicit data on
demographics, drug use history, HIV risk behavior, HIV
testing, access and utilization of harm reduction services.
Interviews were held in confidence, in a room of the SEP,
between the IDU participant and the interviewer. Recruit-
ment was conducted and the survey administrated by a
team of trained fieldworkers. The study protocol included
pre- and post-HIV test counseling for study participants.
Venous blood was collected from participants and tested
with commercially available kits for HIV antibodies
(using Abbott IMx HIV-1/HIV-2 III Plus from Abbott Lab-
oratories, Abbott Park, Illinois, USA) and hepatitis C virus
(HCV) antibodies (using ETI-AB-HCVK-3 from DiaSorinHarm Reduction Journal 2009, 6:3 http://www.harmreductionjournal.com/content/6/1/3
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S.p.A, Via Crescentino, 13040 Saluggia, Italy). HIV test
kits have proved to have high sensitivity and specificity (>
99%) [22,23]. The testing was conducted at the HIV/AIDS
reference laboratory of the Tallinn Merimetsa Hospital.
IDUs were categorized into two groups, pharmacy or SEP
(which included IDUs who got their syringes from SEP
outreach workers), based on their self-reported main
source for syringes within the previous six months. Risk
behaviours and characteristics were compared between
the two groups.
Descriptive statistics, including mean, standard deviation
(SD) and range were used for continuous variables. For
categorical variables, percentages and absolute (n) fre-
quencies are presented. Student's t-test was used for con-
tinuous variables and chi-square test for categorical
variables to explore differences. Odds ratios (OR) and
95% confidence intervals (95% CI) together with p-values
were used to compare characteristics and risk factors
between groups. Multivariate analysis based on concep-
tual hierarchical framework [24] was conducted to
explore factors associated with using pharmacies as a
main source of syringes. We also included factors that
reached a statistically significant p-value (p < 0.05).
Adjusted odds ratios (AOR) were calculated using gender,
age, employment status, duration of injection career and
frequency of injecting per day as control variables in a
logistic regression model. Analyses were carried out using
Stata 9 software [25].
The Ethics Review Board at the University of Tartu
approved the study procedures.
Results
Three hundred and fifty IDUs completed the question-
naire. A total of 99% answered that they had received new
and unused syringes during the previous six months. The
sources for new and unused syringes in that six month
period were: pharmacies, 80%; SEPs, 72%; SEP outreach
workers, 37%; friends, 23%; other drug users, 6%; drug
workers and drug agencies, 4%; sexual partners, 2%; and
street vendors, 1% (multiple responses allowed).
Of the 350 current IDUs recruited in Tallinn 328 (94%)
were retained for the further analysis: 59% (n = 195)
reported using SEP/SEP outreach and 41% (n = 133)
reported using a pharmacy as the main source for sterile
needles. We excluded 22 participants who reported alter-
native main source for sterile syringes from the two under
consideration.
Twenty eight (21%) of the IDUs in the pharmacy group
used also SEP outreach workers as an additional source for
new syringes, and 68 (51%) used the SEP site as an addi-
tional source of syringes. However, 59 (45%) of the IDUs
in the pharmacy group reported that they had never used
SEPs. 132 (68%) of the IDUs in the SEP category had also
used a pharmacy as an additional source of syringes.
Table 1 presents the univariate comparisons of IDUs in
the pharmacy and SEP groups. The majority of the partic-
ipants were male. The ages of the two groups were similar
(mean 26.3 years, range 17 to 54 years, SD = 5.6 for phar-
macy workers and mean 26.9 years, range 17 to 50 years,
SD = 5.7 for SEP users). There were no differences in eth-
nicity, marital status or educational level. There were
modest statistical differences between the factors of
employment and health insurance. Pharmacy users were
more likely to have regular or temporary employment
than SEP users (61% versus 48%, p = 0.024), and more
likely to have health insurance (50% vs. 38%, p = 0.040).
There were no differences in mean age at IDU initiation
between the SEP (18.4 years, range 10 to 42 years, SD =
4.8) and pharmacy users (19.1 years, range 9 to 39 years,
SD = 4.4). However there were significant differences in
terms of the proportion of new injectors (IDUs with 0 to
2 years of injecting) and frequency of injecting daily
between the two groups (Table 1). Pharmacy users were
more likely to be new injectors (16% vs. 6%, p = 0.002)
and less likely to inject daily (62% vs. 76%, p = 0.009).
They also reported lower injecting frequency on the last
day they injected, with 75% of pharmacy users and 89%
of SEP users reporting more than one injection per day (p
= 0.002). There were fewer fentanyl users among phar-
macy users (74% vs 85%, p = 0.015), but no differences in
terms of either injecting amphetamine or experiencing
drug related overdoses. There was no difference in sharing
practices between the groups, except that fewer pharmacy
users reported sharing syringes with HIV positive individ-
uals (71% vs. 82%, p = 0.024). However, pharmacy users
reported riskier sexual behaviors – with a higher propor-
tion reporting more than one sexual partner (53% vs.
40%, p = 0.020) within the preceding year and more
reporting casual sexual partners (47% vs. 32%, p = 0.007)
within previous six months.
There were important differences in HIV/HCV serostatus
between the groups: fewer IDUs in the pharmacy group
were HIV seropositive (46% vs. 64.0%, p = 0.001) or HCV
seropositive (88% vs. 99%, p < 0.001). There were no dif-
ferences in HIV testing prior to the study, having received
drug abuse treatment or having been in prison.
We used the SEP users as a reference group to calculate the
AORs and 95% CI for the pharmacy group for injection
risk behavior, HIV and HCV serostatus, sexual behaviour
and contacts with harm reduction and health services, see
Table 2. Pharmacy users had close to twice the odds forHarm Reduction Journal 2009, 6:3 http://www.harmreductionjournal.com/content/6/1/3
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Table 1: Univariate comparisons between factors1 and main sources for new and unused syringes
Pharmacy SEP2
Variable n % n % OR 95% CI p-value
Gender:
Male 118 88.72 160 82.05 1.72 0.90–3.30 0.102
Female 15 11.28 35 17.95 1.0
Age:
< 20 12 9.02 9 4.62 2.41 0.91–6.35 0.075
20–24 41 30.83 60 30.77 1.23 0.68–2.23 0.486
25–29 49 36.84 70 35.90 1.26 0.71–2.24 0.420
> 30 31 23.31 56 28.72 1.0
Ethnicity:
Russian 106 84.80 168 87.05 0.83 0.44–1.58 0.571
Estonian 19 15.20 25 12.95 1.0
Marital status:
Single 96 72.73 156 80.83 0.63 0.37–1.07 0.087
Married or cohabiting 36 27.27 37 19.17 1.0
Educational level:
< 9 years 72 54.55 100 51.28 0.72 0.17–2.97 0.650
10–12 years 56 42.42 91 46.67 0.62 0.15–2.56 0.504
> 12 years 4 3.03 4 2.05 1.0
Main source of income in last 6 months:
Other 52 39.10 101 51.79 0.60 0.38–0.93 0.024
Regular or temporary job 81 60.90 94 48.21 1.0
Having health insurance:
No 65 50.00 120 61.54 1.0
Yes 65 50.00 75 38.46 1.60 1.02–2.51 0.040
Duration of injection career:
0–2 years 22 16.54 11 5.70 3.74 1.65–8.51 0.002
3–5 years 30 22.56 30 15.54 1.87 0.99–3.54 0.054
6–9 years 42 31.58 79 40.93 0.99 0.58–1.71 0.986
> 10 years 39 29.32 73 37.82 1.0
Frequency of injecting:
Less than daily 50 37.59 47 24.10 1.0
Daily 83 62.41 148 75.90 0.53 0.33–0.85 0.009
Intensity of injecting per day:
One 33 24.81 22 11.34 1.0
More than one 100 75.19 172 88.66 0.39 0.21–0.70 0.002
Main drug injected during last 6 months:
Fentanyl 98 74.24 166 85.13 0.50 0.29–0.88 0.015
Amphetamine 71 53.38 98 50.26 1.13 0.72–1.76 0.578
Ever overdosed:
No 52 39.10 61 31.28 1.0
Yes 81 60.90 134 68.72 0.71 0.45–1.12 0.144
Sharing syringes during last 6 months:
No 82 62.12 128 65.98 1.0
Yes 50 37.88 66 34.02 1.18 0.75–1.87 0.475
Sharing paraphernalia during last 6 months:
No 102 76.69 153 79.27 1.0
Yes 31 23.31 40 20.73 1.16 0.68–1.98 0.579
Ever shared needles with someone known to be HIV positive:
No 38 29.46 34 18.48 1.0
Yes 91 70.54 150 81.52 0.54 0.32–0.92 0.024
Sharing needles with sexual partner during last 6 months:
No 30 60.00 45 67.16 1.0
Yes 20 40.00 22 32.84 1.36 0.63–2.92 0.425
Number of sexual partners during last 12 months:
None or one 63 47.37 116 60.42 1.0
More than one 70 52.63 76 39.58 1.70 1.08–2.65 0.020
Number of casual partners during last 6 months:Harm Reduction Journal 2009, 6:3 http://www.harmreductionjournal.com/content/6/1/3
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having, in the previous year, either more than one sexual
partner (AOR 1.88 95% CI 1.17–3.04) or engaging in cas-
ual sexual relationships (AOR 2.09 95% CI 1.24–3.53) in
the last six months. The pharmacy group had lower odds
for being infected with either HIV or HCV (AOR 0.54 95%
CI 0.33–0.87 and 0.10 95% CI 0.02–0.50, accordingly).
The low numbers of participants reporting exclusive phar-
macy or SEP/SEP outreach use prohibited a meaningful
analysis. Nevertheless, while comparing only SEP/SEP
outreach (n = 66) to only pharmacy (n = 68) users we
found similar results to those obtained in the analysis pre-
sented above in terms of employment, health insurance
statuses, but shorter injecting careers, higher numbers of
sexual partners and less frequent injections and lower HIV
status of exclusively pharmacy users in comparison to
exclusively SEP/SEP outreach (data not shown).
Discussion
We found that the great majority of IDUs in Tallinn are
using either SEPs or pharmacies as their primary source
for sterile syringes. Over half the study participants (59%)
mentioned using SEP, whereas 41% reported pharmacy as
their main source of sterile syringes. A similar study con-
duced in Tallinn two years earlier, found lower propor-
tions using SEP, with 46% reporting SEPs including
outreach workers and 50% of the participants reporting
pharmacies as their main sources for sterile syringes [26].
HIV prevalence was high among both those who used
SEPs and those who used pharmacies as their primary
source of sterile syringes. In addition, both groups
reported an unacceptably high rate of sharing syringes,
especially sharing with people who are known to be HIV
positive. Additional measures to reduce sharing, particu-
larly between people who are HIV positive and HIV nega-
tive are urgently needed in Estonia.
There were significant differences between IDUs primarily
using pharmacies and those using SEPs. Also the compar-
ison of IDUs who used only SEPs or only pharmacies
showed the same results suggesting that there are two dis-
tinct groups of IDUs with different risk profiles using
pharmacies and SEPs. Pharmacy users were more likely to
report multiple sexual partners and casual sexual partners.
Condom use with casual and main partners was, however,
equally low in both groups. This finding suggests that
interventions which increase awareness of the risks associ-
ated with sexual transmission of HIV are also needed.
Our findings suggest that IDUs in the initial stages of their
injection careers use pharmacies. According to the univar-
iate analysis, pharmacy users included a higher propor-
tion of new injectors (those reporting injecting two years
or less) and reported lower injection frequencies. Previous
studies from other locations have reported similar results:
pharmacy users tend to be younger [27-29], with shorter
injecting careers [29,30] and lower injecting frequencies
[29,30]. New injectors create special problems for HIV
prevention. Studies have found higher rates of injecting
risk behavior and a higher incidence of blood-borne infec-
tions among new injectors [16,31-33]. Recent cohort
None 71 53.38 133 68.21 1.0
One or more 62 46.62 62 31.79 1.87 1.19–2.95 0.007
Condom use with casual partner during last 6 months:
Never 12 19.35 11 17.19 1.0
Occasionally/Always 50 80.65 53 82.81 0.86 0.35–2.14 0.753
Condom use with primary partner during last 6 months:
Never 32 48.48 45 47.37 1.0
Occasionally/Always 34 51.52 50 52.63 0.96 0.51–1.79 0.889
Self-reported STI (syphilis, gonorrhea, chlamydia, genital herpes):
No 119 89.47 173 88.72 1.0
Yes 14 10.53 22 11.28 0.93 0.46–1.88 0.830
Disease serostatus:
HIV+ 61 45.86 123 64.06 0.48 0.30–0.75 0.001
HCV+ 117 87.97 190 98.96 0.08 0.02–0.34 0.001
Ever had HIV test:
No 22 16.54 25 12.89 1.0
Yes 111 83.46 169 87.11 0.75 0.40–1.39 0.356
Ever received drug treatment:
No 82 61.65 115 58.97 1.0
Yes 51 38.35 80 41.03 0.89 0.57–1.40 0.627
Ever been in prison:
No 57 42.86 75 38.46 1.0
Yes 76 57.14 120 61.54 0.83 0.53–1.30 0.426
1Reference group SEP users.
2Includes Syringe Exchange Program outreach workers as the source of new and unused syringes.
Table 1: Univariate comparisons between factors1 and main sources for new and unused syringes (Continued)Harm Reduction Journal 2009, 6:3 http://www.harmreductionjournal.com/content/6/1/3
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studies confirm the same, recent initiates to injecting have
a higher incidence of HIV and hepatitis C [34,35]. New
injectors may increase the size of the local IDU popula-
tion, increasing the need for prevention and treatment
services. Also they may not self identify as IDUs, may not
fully appreciate the need to protect themselves against
HIV and other blood-borne diseases, and may find HIV
prevention and drug services difficult to access.
In our study, nearly half the pharmacy users had never
attended needle exchange, similar to a US study where
pharmacy users were less likely to report recent SEP use
[28]. This finding suggests that there could be IDUs who
are beyond the reach of harm reduction services. One pos-
sible solution could be if pharmacies can take a role in
linking IDUs with SEP services, especially for recent initi-
ates. There are several examples in Europe, Australia, New
Table 2: Multivariate factors1 related to pharmacy as main source for syringes2
Variable AOR 95% CI p-value
Main drug injected during last 6 months:
Fentanyl 0.62 0.34–1.13 0.120
Amphetamine 1.13 0.71–1.80 0.609
Ever overdosed:
No 1.0
Yes 0.88 0.53–1.45 0.606
Sharing syringes during last 6 months:
No 1.0
Yes 1.42 0.87–2.32 0.159
Sharing paraphernalia during last 6 months:
No 1.0
Yes 1.33 0.76–2.34 0.312
Ever shared needles with someone known to be HIV positive:
No 1.0
Yes 0.70 0.40–1.23 0.214
Sharing needles with sexual partner during last 6 months:
No 1.0
Yes 1.48 0.65–3.36 0.346
Number of sexual partners during last 12 months:
None or one 1.0
More than one 1.88 1.17–3.04 0.009
Number of casual partners during last 6 months:
None 1.0
One or more 2.09 1.24–3.53 0.006
Condom use with casual partner during last 6 months:
Never 1.0
Occasionally/Always 1.01 0.69–1.47 0.962
Condom use with primary partner:
Never 1.0
Occasionally/Always 0.75 0.38–1.48 0.406
Self-reported STI (syphilis, gonorrhea, chlamydia, genital herpes):
No 1.0
Yes 0.82 0.39–1.74 0.613
Disease serostatus:
HIV+ 0.54 0.33–0.87 0.012
HCV+ 0.10 0.02–0.50 0.005
Ever been tested for HIV:
No 1.0
Yes 1.11 0.56–2.17 0.766
Ever received drug treatment:
No 1.0
Yes 1.16 0.71–1.89 0.548
Ever been in prison:
No 1.0
Yes 1.11 0.67–1.86 0.680
1Reference group SEP users.
2 Adjusted for age, gender, employment status, duration of injection career and intensity of injecting per day.Harm Reduction Journal 2009, 6:3 http://www.harmreductionjournal.com/content/6/1/3
Page 7 of 8
(page number not for citation purposes)
Zealand, and the United States where pharmacies have
been involved in providing services for drug users [8-
10,27]. Despite some concerns for safety and about
improperly discarded syringes, as well as undesired effects
that drug users might have on the sensitivities of other
business customers [8,28,36,37] it has been feasible to
recruit pharmacists to provide services to IDUs [38,39]
and to cultivate a public health perspective among phar-
macists [36,40,41].
Our study has some limitations. The cross-sectional study
design does not allow us to establish a causal relationship
or a direction of causality. Second, we used a non-proba-
bility sample that may have implications for the repre-
sentativeness of the study. However, we used RDS for
recruitment in order to overcome some of the limitations
of convenience sampling [17,18]. The statistical theory
upon which RDS is based suggests that if peer recruitment
proceeds through a sufficiently large number of waves, the
composition of the sample will stabilize, becoming inde-
pendent of the seeds from which recruitment began, and
thereby overcoming any bias the nonrandom choice of
seeds may have introduced [17,18]. Based on our results,
the equilibrium state was achieved. Also, there might be
residual (non-differential) misclassification due to the
way we defined our study groups (pharmacy or SEP/SEP
outreach users) leading to bias. Given that there were still
statistically significant behavioral and HIV status differ-
ences between the groups, however, this supports rather
than detracts from the contention that these two groups
are significantly different.
Studies conducted in Russia and Eastern Europe have
stressed the need for additional sources of syringes besides
SEPs [42,43]. This study indicates the different profiles
between IDUs who mainly use pharmacies for getting
sterile syringes and those who mainly use SEPs. Data on
the risk profiles of different groups of IDUs may be useful
for developing targeted interventions. Encouraging phar-
macies not only to sell sterile injection equipment to
IDUs, as a regulated alternative to SEPs, but also to pro-
vide linkages to other services may be widely applicable in
those areas where injecting drug use is a major driving
force in HIV transmission.
Conclusion
Our results show that pharmacy users were at a less
"advanced" stage of their injection career than SEP users.
This result reinforces the need for a comprehensive
approach and the need for additional sources for acquir-
ing syringes besides SEPs. Strategies to expand syringe
access should be combined with other harm reduction
services to make both sources more effective and easily
utilized.
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